TY - JOUR
T1 - Validation of a Patient Global Assessment for extent, severity and impact to define the severity strata for the Self Assessment Vitiligo Extent Score (SA-VES)
AU - van Geel, N.
AU - Uitentuis, S. E.
AU - Zuidgeest, M.
AU - Wolkerstorfer, A.
AU - Bekkenk, M. W.
AU - Moock, C.
AU - van Goethem, C.
AU - Verlaeckt, E.
AU - Smet, C.
AU - Grine, L.
AU - Speeckaert, R.
N1 - Funding Information: The research activities of N. van Geel were supported by the Scientific Research Foundation‐Flanders (FWO Senior Clinical Investigator: 1831512N), Leo Foundation grant (Leo Foundation project reference number LF16092) and EADV project proposal 2015‐030. Funding Information: We thank all participating patients of this study as well as the Dutch Society for Vitiligo patients (Vitiligo.nl). We thank S. Prinsen for the support related to the methodology during the construction stage of the study. The research activities of N. van Geel are supported by the Scientific Research Foundation‐Flanders (FWO Senior Clinical Investigator: 1831512N), EADV (project proposal: 2015‐030) and Leo Foundation grant (Leo Foundation project reference number LF16092). Funding Information: We thank all participating patients of this study as well as the Dutch Society for Vitiligo patients (Vitiligo.nl). We thank S. Prinsen for the support related to the methodology during the construction stage of the study. The research activities of N. van Geel are supported by the Scientific Research Foundation-Flanders (FWO Senior Clinical Investigator: 1831512N), EADV (project proposal: 2015-030) and Leo Foundation grant (Leo Foundation project reference number LF16092). Publisher Copyright: © 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/1
Y1 - 2021/1
N2 - Background: The Self Assessment Vitiligo Extent Score (SA-VES) is a validated, patient-reported outcome measure to assess the body surface area affected with vitiligo. Information on how to translate the obtained score into extent, severity and impact strata (mild–moderate–severe) is still lacking. Stratification is helpful to define inclusion criteria for trials, enables comparison and pooling of trial results and can be used for epidemiological research. Objectives: The aim was to develop extent, severity and impact strata for the SA-VES based on validated anchor-based questions. Methods: In total, 315 patients with vitiligo (non-segmental; age ≥ 16) recruited at the Ghent University Hospital (Belgium) completed a questionnaire that was conducted in cooperation with the Dutch Society for vitiligo patients to ensure content validity. First three anchor questions included in the questionnaire [Patient Global Assessment (PtGA) for vitiligo extent, severity and impact] were assessed for content validity, construct validity and intrarater reliability. Subsequently, the PtGAs were used to stratify the SA-VES based on ROC analysis. Results: For all PtGAs (PtGA extent, PtGA severity, PtGA impact), at least 75% of hypotheses evaluated for construct validity were confirmed. Intrarater reliability of all PtGAs was good to excellent (ICCs PtGA extent: 0.623; PtGA severity: 0.828; PtGA impact: 0.851). The optimal cut-off values of the SA-VES between the three global categories (mild/limited – moderate – severe/extensive) were 1.05% and 6.45% based on PtGA extent, 2.07% and 4.8% based on PtGA severity and 2% and 3.35% based on PtGA impact. Conclusion: This study provides the first guide for the interpretation of the numerical output obtained by the SA-VES (vitiligo extent) and enables the translation into a global vitiligo grading for extent, severity and impact. As patients’ interpretation of vitiligo extent, severity and impact may vary amongst patients worldwide, future international studies will be required.
AB - Background: The Self Assessment Vitiligo Extent Score (SA-VES) is a validated, patient-reported outcome measure to assess the body surface area affected with vitiligo. Information on how to translate the obtained score into extent, severity and impact strata (mild–moderate–severe) is still lacking. Stratification is helpful to define inclusion criteria for trials, enables comparison and pooling of trial results and can be used for epidemiological research. Objectives: The aim was to develop extent, severity and impact strata for the SA-VES based on validated anchor-based questions. Methods: In total, 315 patients with vitiligo (non-segmental; age ≥ 16) recruited at the Ghent University Hospital (Belgium) completed a questionnaire that was conducted in cooperation with the Dutch Society for vitiligo patients to ensure content validity. First three anchor questions included in the questionnaire [Patient Global Assessment (PtGA) for vitiligo extent, severity and impact] were assessed for content validity, construct validity and intrarater reliability. Subsequently, the PtGAs were used to stratify the SA-VES based on ROC analysis. Results: For all PtGAs (PtGA extent, PtGA severity, PtGA impact), at least 75% of hypotheses evaluated for construct validity were confirmed. Intrarater reliability of all PtGAs was good to excellent (ICCs PtGA extent: 0.623; PtGA severity: 0.828; PtGA impact: 0.851). The optimal cut-off values of the SA-VES between the three global categories (mild/limited – moderate – severe/extensive) were 1.05% and 6.45% based on PtGA extent, 2.07% and 4.8% based on PtGA severity and 2% and 3.35% based on PtGA impact. Conclusion: This study provides the first guide for the interpretation of the numerical output obtained by the SA-VES (vitiligo extent) and enables the translation into a global vitiligo grading for extent, severity and impact. As patients’ interpretation of vitiligo extent, severity and impact may vary amongst patients worldwide, future international studies will be required.
UR - http://www.scopus.com/inward/record.url?scp=85090063840&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/jdv.16562
DO - https://doi.org/10.1111/jdv.16562
M3 - Article
C2 - 32452565
SN - 0926-9959
VL - 35
SP - 216
EP - 221
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
IS - 1
ER -